The firm said its remaining employees will focus on developing the pol theta inhibitor RP-3467 and the PLK4 inhibitor RP-1664.

The company said the move demonstrates the board of directors' confidence in the potential of its PARP1/2 inhibitor in ovarian cancer.

ABI-201 is undergoing IND-enabling studies and uses the same capsid as the firm's clinical-stage gene therapy candidate for wet AMD.

In a recent trial, researchers found that Xpovio plus chemo had activity in NSCLC patients with KRAS mutations other than ...

Based on early Phase I/II data, investigators at Cincinnati Children's are enrolling more patients with a telomere biology ...

The first patient, who had xerostomia linked with Sjögren's disease, received the autologous cell therapy as part of a Phase ...

The committee supports approving the CFTR modulator for patients 2 years and older with at least one non-class I CFTR gene mutation.

The firm said it will rely on academic partnerships and contract manufacturers to support its cell therapy clinical trials.

The European Commission had requested the committee consider new data on the drug that became available after it had adopted its positive opinion.

Krystal said it is on track to launch Vyjuvek in Germany in the middle of the year and in France later in 2025.

Approval would expand the use of Enhertu to breast cancer patients with nearly undetectable HER2 levels in their tumors.

SciClone will develop and distribute Tasfygo in greater China but Eisai will retain worldwide rights outside the region.